Back to top
more

Theravance Biopharma (TBPH)

(Real Time Quote from BATS)

$9.20 USD

9.20
106,191

-0.02 (-0.22%)

Updated Apr 24, 2024 02:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TBPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 102 327 173 293 281
Receivables 17 17 14 16 22
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 14 9 62 85 36
Total Current Assets 134 353 250 393 338
Net Property & Equipment 9 12 14 16 13
Investments & Advances 0 0 68 13 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 203 202 4 3 6
Total Assets 382 607 375 469 409
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 2 2 3 7 5
Current Portion Long-Term Debt 0 0 17 19 10
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 13 20 38 76 58
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 6 0 0 12 32
Total Current Liabilities 25 29 59 124 112
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 7
Convertible Debt 0 0 228 227 226
Long-Term Debt 0 0 371 373 219
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 99 91 2 2 21
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 169 166 713 773 633
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,122 1,296 1,387 1,223 1,025
Retained Earnings -909 -854 -1,726 -1,527 -1,249
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 213 442 -339 -304 -224
Total Liabilities & Shareholder's Equity 382 607 375 469 409
Total Common Equity 213 442 -339 -304 -224
Shares Outstanding 49.80 67.30 73.70 63.90 56.70
Book Value Per Share 4.28 6.56 -4.59 -4.75 -3.95

Fiscal Year End for Theravance Biopharma, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 102 134 167 241
Receivables NA 17 17 16 12
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 14 11 9 8
Total Current Assets NA 134 162 192 261
Net Property & Equipment NA 9 9 10 12
Investments & Advances NA 0 0 0 19
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 203 205 207 207
Total Assets NA 382 414 447 539
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 2 2 2 3
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 13 13 14 16
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 6 0 0 0
Total Current Liabilities NA 25 25 25 26
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 101 99 98
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 169 167 166 168
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,122 1,147 1,172 1,247
Retained Earnings NA -909 -901 -892 -876
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 213 246 280 371
Total Liabilities & Shareholder's Equity NA 382 414 447 539
Total Common Equity 0 213 246 280 371
Shares Outstanding 48.10 49.80 52.80 57.80 63.20
Book Value Per Share 0.00 4.28 4.66 4.85 5.86